Chromosome 17q12-21 is known to contain a gene (or genes) which confers susceptibility to early-onset breast cancer and ovarian cancer (BRCA1). Identification and isolation of BRCA1 will likely provide the basis for increased understanding of the pathogenesis of breast and ovarian cancer, the development of targeted diagnostic and therapeutic approaches and a means of screening women at risk of being gene carriers. The thyroid hormone receptor-alpha (THRA1) locus and the anonymous DNA segment D17S579 flank this region, thought to be approximately 2 centimorgans (cM) in length. We have cloned approximately 80% of this region in yeast artificial chromosomes (YACs) and identified cosmids spanning the majority of these YACs using PCR amplification of inter-Alu segments. We are now prepared to begin the task of identifying transcripts from this region in order to isolate BRCA1. We propose to employ a variety of transcript-identification strategies in order to achieve this goal. These include: 1) Direct cDNA screening with YACs and cosmids from within the BRCA1 region. cDNA libraries will be derived from normal breast and ovarian tissue for BRCA1 candidate transcripts. Candidate transcripts will be analyzed by expected tissue distribution and the presence of germline mutations in affected individuals from families thought to be linked to BRCA1. 2) Exon trapping strategies. Cosmids from the BRCA1 region will be subcloned into plasmid vectors designed to assist in the identification of exon/intron splice junctions within cloned DNA segments. Plasmid subclones containing exons will be used to screen appropriate cDNA libraries for BRCA1 candidate transcripts. 3) Solution hybridization of cosmid DNA PCR-amplified using biotinylated primers with cDNA from breast or ovarian tissue. These double-stranded DNA complexes will be conjugated to magnetic beads for rapid isolation and analyzed as described above. 4) Direct screening of breast and ovarian cDNA libraries with microdissected material from the BRCA1 region. 5) Subtractive hybridization. We plan to combine a PCR-based method for fingerprinting mRNA from specific tissues with the technique utilizing magnetic beads for isolation of cDNAs from individual cosmids. This approach should allow selective identification of unique mRNA fragments from the BRCA1 region which are present in normal breast and ovary but absent in tumors arising from these tissues. Current evidence suggests that BRCA1 is a tumor suppressor gene, thus transcripts encoded by genes in the BRCA1 region which demonstrate this pattern of expression are excellent candidates for BRCA1.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA061231-01
Application #
3204701
Study Section
Special Emphasis Panel (SRC (56))
Project Start
1993-07-01
Project End
1997-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Gronwald, Jacek; Tung, Nadine; Foulkes, William D et al. (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281-4
Jernstrom, H; Lubinski, J; Lynch, H T et al. (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094-8
Narod, S A; Sun, P; Ghadirian, P et al. (2001) Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 357:1467-70
Lakhani, S R; Gusterson, B A; Jacquemier, J et al. (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6:782-9
Brunet, J S; Ghadirian, P; Rebbeck, T R et al. (1998) Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst 90:761-6
Lakhani, S R; Jacquemier, J; Sloane, J P et al. (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138-45
(1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349:1505-10
Thakur, S; Zhang, H B; Peng, Y et al. (1997) Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 17:444-52
Couch, F J; Rommens, J M; Neuhausen, S L et al. (1996) Generation of an integrated transcription map of the BRCA2 region on chromosome 13q12-q13. Genomics 36:86-99
Abel, K J; Brody, L C; Valdes, J M et al. (1996) Characterization of EZH1, a human homolog of Drosophila Enhancer of zeste near BRCA1. Genomics 37:161-71

Showing the most recent 10 out of 14 publications